Abraxis BioScience
| Industry | Pharmaceutical |
|---|---|
| Founded | 2001 in Los Angeles, California[1] |
| Founder | Dr. Patrick Soon-Shiong |
| Defunct | 2010 |
| Headquarters | Los Angeles , USA |
Key people | Mr. Rick Click, Chief Information Officer and Global IT Officer; Dr. Nguyen V. Dat Ph.D., Vice President of Clinical Research |
| Products | Protein-based therapeutics and technologies for treatment of cancer and other critical illnesses |
| Brands | Abraxane |
| Services | Cancer drugs |
| Owner | Celgene |
Abraxis BioScience was a global biopharmaceutical company that developed treatments for critically ill patients. It had over 2000 employees worldwide inb 2007.[2] Abraxis's portfolio included the world's first protein-based nanoparticle chemotherapeutic compound, called nab Technology.[3] From this the company developed Abraxane, a treatment for metastatic breast cancer.[4]
In 2010, Abraxis BioScience was acquired by Celgene Corporation.[5]
History
Abraxis was incorporated in 2001 in Los Angeles.[1] Besides cancer treatments, it provided treatment for multiple sclerosis, Alzheimer's, and some cardiovascular diseases.[1] It had manufacturing plants in Melrose Park, Illinois and Phoenix, Arizona.[1]
In August 2007, Abraxis announced it would undergo a restructuring to separate its "hospital-based products business" from its "proprietary products business" into two public companies; this would involve the merging of Abraxis Oncology and Abraxis Research subunits to form a new Abraxis Bioscience (Abraxis Bioscience, Inc., Nasdaq: ABII), and the spinoff of Abraxis Pharmaceutical Products (APP, Inc., Nasdaq: APPX).[6] This reorganization was completed in November 2007.[7] During the reorganization, the new Abraxis Bioscience was known briefly as New Abraxis.[7]
In 2010, Abraxis BioScience was acquired by Celgene Corporation.[8] Per Celgene's website, as of at least 2016 Abraxis no longer exists as a named division within Celgene.
References
- ^ a b c d "Company Overview of Abraxis BioScience, Inc". Bloomberg. Retrieved October 17, 2016.
- ^ BioPortfolio, 2007, "InDepth Summary", 10/11/2009[dead link]
- ^ Abraxis BioScience, 2008, "Nab Technology", 10/11/2009
- ^ Hoovers.[dead link]
- ^ Celgene, 30 June 2010, "Celgene To Acquire Abraxis BioScience Inc." (press release), 8/6/2015.
- ^ Van Arnum, Patricia (1 August 2007). "Abraxis BioScience Plans to Separate into Two Companies". Pharmaceutical Technology. Retrieved 2015-08-07 – via Highbeam Research.
- ^ a b Gopalakrishnan, Lisa (13 November 2007). FORM 8-K (Report). United States Securities and Exchange Commission. Retrieved 2015-08-07.
- ^ Celgene, 30 June 2010, "Celgene To Acquire Abraxis BioScience Inc." (press release), 8/6/2015.
External links
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
- Biotechnology companies of the United States
- Pharmaceutical companies of the United States
- Biotechnology companies established in 2001
- Pharmaceutical companies established in 2001
- 2001 establishments in California
- Biotechnology companies disestablished in 2010
- 2010 disestablishments in California
- Health care companies based in California
- Medical company stubs